Literature DB >> 10964869

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

L L Judd1, M J Paulus, P J Schettler, H S Akiskal, J Endicott, A C Leon, J D Maser, T Mueller, D A Solomon, M B Keller.   

Abstract

OBJECTIVE: This study investigated the influence of incomplete recovery from first lifetime major depressive episodes on long-term outcome.
METHOD: After their first lifetime major depressive episode, patients were divided into asymptomatic (N=70) and residual subthreshold depressive symptom (N=26) recovery groups and compared on longitudinal course during up to 12 years of prospective naturalistic follow-up.
RESULTS: Patients with residual subthreshold depressive symptoms during recovery had significantly more severe and chronic future courses. Those with residual symptoms relapsed to major and minor depressive episodes faster and had more recurrences, shorter well intervals, and fewer symptom-free weeks during follow-up than asymptomatic patients.
CONCLUSIONS: Resolution of major depressive episodes with residual subthreshold depressive symptoms, even the first lifetime episode, appears to be the first step of a more severe, relapsing, and chronic future course. When ongoing subthreshold symptoms continue after major depressive episodes, the illness is still active, and continued treatment is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964869     DOI: 10.1176/appi.ajp.157.9.1501

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  102 in total

1.  Assessment of subclinical symptoms and psychological well-being in depression.

Authors:  G A Fava; L Mangelli
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

Review 2.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

3.  Augmenting antidepressant medication treatment of depressed women with emotionally focused therapy for couples: a randomized pilot study.

Authors:  Wayne H Denton; Andrea K Wittenborn; Robert N Golden
Journal:  J Marital Fam Ther       Date:  2012-05-15

4.  Calibration of response and remission cut-points on the Beck Depression Inventory-Second Edition for monitoring seasonal affective disorder treatment outcomes.

Authors:  Gloria M Reeves; Kelly J Rohan; Patricia Langenberg; Soren Snitker; Teodor T Postolache
Journal:  J Affect Disord       Date:  2012-01-25       Impact factor: 4.839

5.  Enhancement of Treatment Response in Depression in the Primary Care Setting.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

6.  Diagnosing and treating depression earlier and preventing recurrences: still neglected after all these years.

Authors:  John F Greden
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

7.  Managing depression in primary care: achieving remission.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

8.  Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders.

Authors:  Carlos M Grilo; Charles A Sanislow; John G Gunderson; Maria E Pagano; Shirley Yen; Mary C Zanarini; M Tracie Shea; Andrew E Skodol; Robert L Stout; Leslie C Morey; Thomas H McGlashan
Journal:  J Consult Clin Psychol       Date:  2004-10

Review 9.  Evidence for the management of adolescent depression.

Authors:  R Eric Lewandowski; Mary C Acri; Kimberly E Hoagwood; Mark Olfson; Greg Clarke; William Gardner; Sarah Hudson Scholle; Sepheen Byron; Kelly Kelleher; Harold A Pincus; Samantha Frank; Sarah M Horwitz
Journal:  Pediatrics       Date:  2013-09-16       Impact factor: 7.124

Review 10.  Prevalence and outcome of partial remission in depression.

Authors:  Richard Tranter; Claire O'Donovan; Praful Chandarana; Sidney Kennedy
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.